Laurie Glimcher, Dana-Farber president and CEO (Getty Images)
January 15, 2021 07:38 AM ESTUpdated 11:47 AM
Financing

With its rank-and-file churn­ing out star­tups, Dana-Far­ber launch­es ven­ture fund to cap­i­tal­ize on that suc­cess

Nicole DeFeudis

Editor

The pace of in­no­va­tion at the Dana-Far­ber Can­cer In­sti­tute in re­cent years has seen a wave of star­tups launch with IP or lead­er­ship sourced from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sen­a­tors ask FDA to dig in­to 'mis­lead­ing' Su­per Bowl ad from Hims

Pli­ant paus­es Phase 2b lung fi­bro­sis study af­ter safe­ty board rec­om­men­da­tion, shares plum­met

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

Up­dat­ed: Bay Area biotech VC to shut down 15 months af­ter launch, sources say, af­ter key in­vestor pulls out

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times